A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Lurbinectedin (Primary) ; Topotecan
- Indications Ovarian cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors PharmaMar
- 20 Mar 2017 Results published in the Annals of Oncology
- 01 Nov 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History